Diagnosis Code Z79.811
Information for Medical Professionals
The following edits are applicable to this code:
Unacceptable principal diagnosis Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual’s health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.
Convert to ICD-9 General Equivalence Map
The ICD-10 and ICD-9 GEMs are used to facilitate linking between the diagnosis codes in ICD-9-CM and the new ICD-10-CM code set. The GEMs are the raw material from which providers, health information vendors and payers can derive specific applied mappings to meet their needs.
- V07.52 - Use aromatase inhibitors
Present on Admission (POA) Present on Admission
The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement.
The code Z79.811 is exempt from POA reporting.
- Long-term current use of aromatase inhibitor
Index of Diseases and Injuries
References found for the code Z79.811 in the Index of Diseases and Injuries:
- Inclusion Terms: Inclusion terms
List of terms is included under some codes. These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of “other specified” codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
- Long term (current) use of anastrozole (Arimidex)
- Long term (current) use of exemestane (Aromasin)
- Long term (current) use of letrozole (Femara)
Information for Patients
Breast cancer affects one in eight women during their lives. No one knows why some women get breast cancer, but there are many risk factors. Risks that you cannot change include
- Age - the risk rises as you get older
- Genes - two genes, BRCA1 and BRCA2, greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested for the genes.
- Personal factors - beginning periods before age 12 or going through menopause after age 55
Other risks include obesity, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35, and having dense breasts.
Symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast, and discharge from a nipple. Breast self-exams and mammography can help find breast cancer early, when it is most treatable. One possible treatment is surgery. It could be a lumpectomy or a mastectomy. Other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.
Men can have breast cancer, too, but it is rare.
NIH: National Cancer Institute
- After chemotherapy - discharge (Medical Encyclopedia)
- BRCA1 and BRCA2 gene testing (Medical Encyclopedia)
- Breast biopsy -- stereotactic (Medical Encyclopedia)
- Breast biopsy -- ultrasound (Medical Encyclopedia)
- Breast cancer (Medical Encyclopedia)
- Breast cancer staging (Medical Encyclopedia)
- Breast lump (Medical Encyclopedia)
- Breast self exam (Medical Encyclopedia)
- Hormone therapy for breast cancer (Medical Encyclopedia)
- Understanding Chemotherapy - NIH - Easy-to-Read (National Cancer Institute)
- What to Know about Brachytherapy (A Type of Internal Radiation Therapy) - NIH - Easy-to-Read (National Cancer Institute)
- What to Know about External Beam Radiation Therapy - NIH - Easy-to-Read (National Cancer Institute)